Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Antignani, Pier Luigi, Ascher, Enrico, Baradaran, Hediyeh, Bokkers, Reinoud P.H., Cambria, Richard P., Comerota, Anthony J., Dardik, Alan, Davies, Alun H., Eckstein, Hans Henning, Faggioli, Gianluca, Fernandes e Fernandes, Jose, Fraedrich, Gustav, Geroulakos, George, Gloviczki, Peter, Golledge, Jonathan, Gupta, Ajay, Jezovnik, Mateja K., Kakkos, Stavros K., Katsiki, Niki, Knoflach, Michael, Eline Kooi, M., Lanza, Gaetano, Lavenson, George S., Liapis, Christos D., Loftus, Ian M., Mansilha, Armando, Millon, Antoine, Nicolaides, Andrew N., Pini, Rodolfo, Poredos, Pavel, Proczka, Robert M., Ricco, Jean Baptiste, Riles, Thomas S., Ringleb, Peter Arthur, Rundek, Tatjana, Saba, Luca, Schlachetzki, Felix, Silvestrini, Mauro, Spinelli, Francesco, Stilo, Francesco, Sultan, Sherif, Suri, Jasjit S., Svetlikov, Alexei V., Zeebregts, Clark J., and Chaturvedi, Seemant (2022) Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis. Angiology, 73 (10). pp. 903-910.

PDF (Published Version) - Published Version Restricted to Repository staff only

 

5

1

Abstract

Despite the publication of several national/international guidelines, the optimal management of patients with asymptomatic carotid stenosis (AsxCS) remains controversial. This article compares 3 recently released guidelines (the 2020 German–Austrian, the 2021 European Stroke Organization [ESO], and the 2021 Society for Vascular Surgery [SVS] guidelines) vs the 2017 European Society for Vascular Surgery (ESVS) guidelines regarding the optimal management of AsxCS patients.

The 2017 ESVS guidelines defined specific imaging/clinical parameters that may identify patient subgroups at high future stroke risk and recommended that carotid endarterectomy (CEA) should or carotid artery stenting (CAS) may be considered for these individuals. The 2020 German–Austrian guidelines provided similar recommendations with the 2017 ESVS Guidelines. The 2021 ESO Guidelines also recommended CEA for AsxCS patients at high risk for stroke on best medical treatment (BMT), but recommended against routine use of CAS in these patients. Finally, the SVS guidelines provided a strong recommendation for CEA+BMT vs BMT alone for low-surgical risk patients with >70% AsxCS. Thus, the ESVS, German–Austrian, and ESO guidelines concurred that all AsxCS patients should receive risk factor modification and BMT, but CEA should or CAS may also be considered for certain AsxCS patient subgroups at high risk for future ipsilateral ischemic stroke.

Actions (Repository Staff Only)

Item Control Page